-
公开(公告)号：US20220348647A1
公开(公告)日：2022-11-03
申请号：US17853218
申请日：2022-06-29
Applicant: Janssen Biotech, Inc.
Inventor： Ken Boakye , Alfred Del Vecchio , John Kehoe , Eilyn Lacy , Lynne Murray , Mary Ryan , Sandra Santulli-Marotto , John Wheeler , Brian Whitaker , Alexey Teplyakov
IPC: C07K16/24
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US10689453B2
公开(公告)日：2020-06-23
申请号：US16382645
申请日：2019-04-12
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US09248194B2
公开(公告)日：2016-02-02
申请号：US14338391
申请日：2014-07-23
Applicant: Janssen Biotech, Inc.
Inventor： Daphne Ann Salick Ryan , John Kehoe , John Wheeler , Chunlin Yang , Abla Creasy
IPC: A61K47/42 , C07K16/24 , A61K39/395 , A61K39/00
CPC classification number: A61K47/42 , A61K39/3955 , A61K2039/505 , C07K7/08 , C07K14/525 , C07K16/241 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.
Abstract translation: 我们已经向英夫利昔单抗公开了亲和肽。 更具体地，我们已经公开了一种亲和力生物基质，其中亲和肽共价连接到生物相容的可生物降解的聚合物上。 亲和力生物基质可用于制备英夫利昔单抗的控制释放装置。
-
4.发明授权公开(公告)号：US10301392B2
公开(公告)日：2019-05-28
申请号：US15596609
申请日：2017-05-16
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US20170066831A1
公开(公告)日：2017-03-09
申请号：US14939624
申请日：2015-11-12
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
Patent Agency Ranking
公开(公告)号：US09090694B2
公开(公告)日：2015-07-28
申请号：US13798204
申请日：2013-03-13
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
公开(公告)号：US11414484B2
公开(公告)日：2022-08-16
申请号：US17060362
申请日：2020-10-01
Applicant: Janssen Biotech, Inc.
Inventor： Ken Boakye , Alfred Del Vecchio , John Kehoe , Eilyn Lacy , Lynne Murray , Mary Ryan , Sandra Santulli-Marotto , John Wheeler , Brian Whitaker , Alexey Teplyakov
Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US20200277393A1
公开(公告)日：2020-09-03
申请号：US16878209
申请日：2020-05-19
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US09683046B2
公开(公告)日：2017-06-20
申请号：US14790144
申请日：2015-07-02
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US08906649B2
公开(公告)日：2014-12-09
申请号：US13760663
申请日：2013-02-06
Applicant: Janssen Biotech, Inc.
Inventor： John Kehoe , Tatiana Ort , Kristen Picha , Mary Ryan , John Wheeler , Jennifer Lee Gardiner
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/92
Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.021 seconds)
